{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:04:01Z","timestamp":1790096641362,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:00:00Z","timestamp":1536883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jtho.2018.07.093","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T13:22:53Z","timestamp":1533648173000},"page":"1897-1905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation\u2013Positive Advanced NSCLC: Findings From a Global Named Patient Use Program"],"prefix":"10.1016","volume":"13","author":[{"given":"Solange","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Curioni-Fontecedro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hovav","family":"Nechushtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gautschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Spataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Unk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Lorence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Carri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Cseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.07.093_bib1","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2018.07.093_bib2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3390\/cancers7020816","article-title":"Targeted therapies in non\u2013small cell lung cancer-beyond EGFR and ALK","volume":"7","author":"Rothschild","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2018.07.093_bib3","unstructured":"US Food and Drug Administration. TAFINLAR. Highlights of prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202806s006lbl.pdf. Accessed March 19,\u00a02018."},{"key":"10.1016\/j.jtho.2018.07.093_bib4","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","article-title":"Somatic mutations of the HER2 kinase domain in lung adenocarcinomas","volume":"65","author":"Shigematsu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.07.093_bib5","first-page":"84","article-title":"Targeted therapy in NSCLC driven by HER2 insertions","volume":"3","author":"Peters","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2018.07.093_bib6","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.07.093_bib7","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazi\u00e8res","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/jamaoncol.2018.0775","article-title":"Association of ERBB mutations with clinical outcomes of afatinib- or erlotinib-treated patients with lung squamous cell carcinoma","volume":"4","author":"Goss","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdv573","article-title":"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort","volume":"27","author":"Mazi\u00e8res","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdu438.47","article-title":"Neratinib (N) with or without temsirolimus (TEM) in patients (pts) with non\u2013small cell lung cancer (NSCLC) carrying HER2 somatic mutations: an international randomized phase II study","volume":"25","author":"Besse","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib11","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc060020","article-title":"HER2 mutation and response to trastuzumab therapy in non\u2013small-cell lung cancer","volume":"354","author":"Cappuzzo","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.07.093_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2018.07.093_bib13","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann Oncol"},{"issue":"suppl 2","key":"10.1016\/j.jtho.2018.07.093_bib14","doi-asserted-by":"crossref","first-page":"S1783","DOI":"10.1016\/j.jtho.2017.09.410","article-title":"OA 14.05 Phase 2 basket trial of ado-trastuzumab emtansine in patients with HER2 mutant or amplified lung cancers","volume":"12","author":"Li","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib15","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1097\/JTO.0000000000000424","article-title":"Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer","volume":"10","author":"Weiler","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib16","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in\u00a0preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2018.07.093_bib17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jtho.2018.07.093_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.lungcan.2012.01.008","article-title":"Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2\/neu","volume":"76","author":"De Gr\u00e8ve","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.07.093_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9071","article-title":"Afatinib in patients with metastatic HER2-mutant lung cancers: an international multicenter study","volume":"35","author":"Lai","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9070","article-title":"A\u00a0single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: the ETOP NICHE trial","volume":"35","author":"Smit","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non\u2013small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib22","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2017-0666","article-title":"Global named patient use program of afatinib in advanced non\u2013small-cell lung carcinoma patients who progressed following prior therapies","author":"Cappuzzo","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib23","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/ijc.22143","article-title":"Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features","volume":"119","author":"Buttitta","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2018.07.093_bib24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2018.07.093_bib25","first-page":"122","article-title":"HER2 driven non\u2013small cell lung cancer (NSCLC): potential therapeutic approaches","volume":"2","author":"Garrido-Castro","year":"2013","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2018.07.093_bib26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/mdh031","article-title":"Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non\u2013small-cell lung cancer","volume":"15","author":"Gatzemeier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib28","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2004.04.105","article-title":"Trastuzumab in the treatment of advanced non\u2013small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598","volume":"22","author":"Langer","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3816\/CLC.2004.n.004","article-title":"Trastuzumab plus docetaxel in HER2\/neu-positive non\u2013small-cell lung cancer: a California Cancer Consortium screening and phase II trial","volume":"5","author":"Lara","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2018.07.093_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8509","article-title":"Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non\u2013small cell lung cancer (mNSCLC)","volume":"35","author":"Stinchcombe","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","article-title":"A\u00a0phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer","volume":"13","author":"Hotta","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib32","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/rp.59.1.1","article-title":"Essential roles of Her2\/erbB2 in cardiac development and function","volume":"59","author":"Negro","year":"2004","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.jtho.2018.07.093_bib34","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.07.093_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0025-6196(11)60840-9","article-title":"Trastuzumab-induced cardiotoxicity: heart failure at the crossroads","volume":"83","author":"Sengupta","year":"2008","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.jtho.2018.07.093_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40959-015-0006-7","article-title":"Cardiac safety of afatinib: a review of data from clinical trials","volume":"1","author":"Ewer","year":"2015","journal-title":"Cardio-Oncology"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418309304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418309304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:38:32Z","timestamp":1761561512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418309304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1556086418309304"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.07.093","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation\u2013Positive Advanced NSCLC: Findings From a Global Named Patient Use Program","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.07.093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}